Quantcast

Health Care Sector Update for 01/09/2018: GBT,PTIE,PSTI,OFIX,AYI


Shutterstock photo

Top Health Care Stocks

JNJ +1.63%

PFE +0.03%

ABT +0.31%

MRK +0.37%

AMGN +1.99%

Health care stocks extended their advance this afternoon, including a more than 0.6% gain for the NYSE Health Care Index in late trade. Also today, shares of health care companies in the S&P 500 were up more than 1.3% as a group while the Nasdaq Biotechnology index was nearly 2.2% higher.

Among health care stocks moving on news today:

Global Blood Therapeutics ( GBT ) was almost 20% higher shortly before Tuesday's closing bell after the early-stage biotech company today said federal regulators have designated its voxelotor disease-modifying treatment of sickle cell disease as a breakthrough therapy. The new designation is intended to accelerate development and agency review of drug demonstrating preliminary clinical evidence for a substantial improvement over available therapy. Voxelotor previously received a priority medicines designation from the European Medicines Agency.

In other sector news:

+ Pain Therapeutics ( PTIE ) more than doubled in price on Tuesday, reaching a 16-month high, after issuing positive late-stage trial results for its Remoxy drug candidate and setting the stage for the company to soon resubmit a new drug application for the abuse-deterrent, extended-release oxycodone pain killer.

+ Pluristem Therapeutics ( PSTI ) rallied after federal regulators approved an Expanded Access Program for its investigational PLX-PAD cell treatment, allowing its use in patients with critical limb ischemia outside of clinical trials where they are often unsuitable for inclusion under study protocols.

+ Orthofix International ( OFIX ) advanced Tuesday after the medical device company today reported preliminary Q4 sales activity beating Wall Street expectations. Sales rose 7.7% during the three months ended Dec. 31 to $117 mln, topping the $112.3 mln analyst mean. It also sees FY18 sales growing between 4% to 5% to a range of $450 mln to $455 mln, also topping the Street view by at least $1.7 mln.

- Acuity Brands ( AYI ) declined after reporting below-consensus fiscal Q1 financial results. It earned $1.94 per share, missing the Capital IQ consensus by $0.08 per share. Revenue fell 1% to $842.8 mln, also trailing the $883.3 mln Street call.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.



This article appears in: Investing , US Markets
Referenced Symbols: GBT , PTIE , PSTI , OFIX , AYI



More from MT Newswires

Subscribe






MT Newswires
Contributor:

MT Newswires

Market News, Commodities








Research Brokers before you trade

Want to trade FX?